UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4525) 4525
Newspaper Article (162) 162
Newsletter (73) 73
Book Chapter (53) 53
Magazine Article (31) 31
Reference (29) 29
Dissertation (5) 5
Conference Proceeding (4) 4
Government Document (4) 4
Book / eBook (2) 2
Book Review (2) 2
Streaming Video (2) 2
Publication (1) 1
Transcript (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3745) 3745
science & technology (3408) 3408
life sciences & biomedicine (3345) 3345
thalidomide - administration & dosage (2240) 2240
male (2172) 2172
thalidomide (2053) 2053
female (2048) 2048
thalidomide - analogs & derivatives (1730) 1730
middle aged (1696) 1696
thalidomide - therapeutic use (1661) 1661
aged (1546) 1546
multiple myeloma - drug therapy (1435) 1435
oncology (1387) 1387
hematology (1284) 1284
adult (1200) 1200
multiple myeloma (1183) 1183
thalidomide - adverse effects (1174) 1174
antineoplastic combined chemotherapy protocols - therapeutic use (1171) 1171
treatment outcome (1119) 1119
biological and medical sciences (1036) 1036
medical sciences (1027) 1027
lenalidomide (804) 804
dexamethasone - administration & dosage (777) 777
bortezomib (676) 676
animals (660) 660
aged, 80 and over (613) 613
care and treatment (586) 586
antineoplastic agents - therapeutic use (504) 504
thalidomide - pharmacology (503) 503
drug therapy (485) 485
antineoplastic combined chemotherapy protocols - adverse effects (480) 480
pharmacology. drug treatments (459) 459
pharmacology & pharmacy (440) 440
chemotherapy (428) 428
abridged index medicus (401) 401
research (396) 396
multiple myeloma - mortality (395) 395
cancer (383) 383
medicine & public health (383) 383
dexamethasone (380) 380
disease-free survival (375) 375
recurrence (364) 364
hematologic and hematopoietic diseases (363) 363
dosage and administration (357) 357
antineoplastic combined chemotherapy protocols - administration & dosage (352) 352
multiple myeloma - pathology (338) 338
boronic acids - administration & dosage (333) 333
pyrazines - administration & dosage (332) 332
dose-response relationship, drug (329) 329
leukemias. malignant lymphomas. malignant reticulosis. myelofibrosis (322) 322
angiogenesis inhibitors - therapeutic use (320) 320
immunopathology (312) 312
immunodeficiencies. immunoglobulinopathies (307) 307
drug administration schedule (305) 305
immunoglobulinopathies (303) 303
antineoplastic agents (302) 302
multiple myeloma - therapy (299) 299
drug therapy, combination (297) 297
prognosis (297) 297
immunosuppressive agents - therapeutic use (291) 291
antineoplastic agents - administration & dosage (287) 287
analysis (283) 283
mice (279) 279
retrospective studies (279) 279
follow-up studies (278) 278
survival analysis (277) 277
dermatology (275) 275
remission induction (273) 273
tumors (272) 272
health aspects (270) 270
angiogenesis inhibitors - administration & dosage (267) 267
survival rate (260) 260
hematology, oncology and palliative medicine (247) 247
risk factors (244) 244
antineoplastic agents - adverse effects (243) 243
clinical trials as topic (243) 243
administration, oral (241) 241
clinical trials (239) 239
combined modality therapy (231) 231
immunosuppressive agents - administration & dosage (224) 224
melphalan - administration & dosage (224) 224
transplantation (224) 224
disease progression (223) 223
transplantation, autologous (223) 223
general & internal medicine (214) 214
cyclophosphamide - administration & dosage (212) 212
medicine, general & internal (209) 209
patients (207) 207
multiple myeloma - complications (206) 206
immunologic factors - therapeutic use (203) 203
multiple myeloma - diagnosis (202) 202
time factors (200) 200
stem cells (197) 197
aids/hiv (186) 186
dexamethasone - therapeutic use (185) 185
angiogenesis inhibitors (184) 184
immunology (184) 184
prednisone - administration & dosage (184) 184
medical research (183) 183
dexamethasone - adverse effects (180) 180
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4679) 4679
Japanese (92) 92
German (51) 51
French (40) 40
Chinese (35) 35
Spanish (24) 24
Czech (14) 14
Portuguese (14) 14
Italian (11) 11
Polish (8) 8
Dutch (5) 5
Hungarian (4) 4
Danish (3) 3
Norwegian (2) 2
Russian (2) 2
Ukrainian (2) 2
Finnish (1) 1
Korean (1) 1
Serbian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


American journal of clinical dermatology, ISSN 1175-0561, 06/2016, Volume 17, Issue 3, pp. 191 - 200
Life Sciences & Biomedicine | Dermatology | Science & Technology | Humans | Protein Kinase Inhibitors - adverse effects | Thiazoles - adverse effects | Thalidomide - analogs & derivatives | Isonicotinic Acids - administration & dosage | Phosphodiesterase 4 Inhibitors - adverse effects | Pyrroles - administration & dosage | Adenosine - adverse effects | Adamantane - therapeutic use | Pyrroles - adverse effects | Adamantane - administration & dosage | Receptors, Lysosphingolipid - metabolism | Adamantane - analogs & derivatives | Isonicotinic Acids - adverse effects | Thalidomide - adverse effects | Biological Therapy | Isonicotinic Acids - therapeutic use | Piperidines - administration & dosage | Psoriasis - drug therapy | Adenosine A3 Receptor Antagonists - therapeutic use | Administration, Oral | Azetidines - adverse effects | Niacinamide - adverse effects | Niacinamide - therapeutic use | Phosphodiesterase 4 Inhibitors - therapeutic use | Adenosine A3 Receptor Antagonists - adverse effects | Thalidomide - administration & dosage | Adenosine - administration & dosage | Protein Kinase Inhibitors - administration & dosage | Azetidines - therapeutic use | Adenosine - analogs & derivatives | Thalidomide - therapeutic use | Sulfonamides - administration & dosage | Niacinamide - analogs & derivatives | Thiazoles - administration & dosage | Thiazoles - therapeutic use | rho-Associated Kinases - antagonists & inhibitors | Phosphodiesterase 4 Inhibitors - administration & dosage | Adenosine - therapeutic use | Arthritis, Psoriatic - drug therapy | Pyrroles - therapeutic use | Adamantane - adverse effects | Adenosine A3 Receptor Antagonists - administration & dosage | Pyrimidines - administration & dosage | Clinical Trials as Topic | Niacinamide - administration & dosage | Biological Factors - therapeutic use | Janus Kinases - antagonists & inhibitors | Azetidines - administration & dosage | Sulfonamides - therapeutic use | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Piperidines - adverse effects | Pyrimidines - adverse effects | Sulfonamides - adverse effects
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 08/2017, Volume 35, Issue 22, pp. 2473 - 2481
Journal Article
The lancet oncology, ISSN 1470-2045, 2010, Volume 11, Issue 10, pp. 934 - 941
Journal Article
British journal of haematology, ISSN 0007-1048, 08/2017, Volume 178, Issue 4, pp. 571 - 582
toxicity | multiple myeloma | proteasome inhibitor | Hematology | dosing | ixazomib | Life Sciences & Biomedicine | Science & Technology | Glycine - analogs & derivatives | Peripheral Nervous System Diseases - chemically induced | Follow-Up Studies | Glycine - adverse effects | Nausea - chemically induced | Humans | Middle Aged | Drug Eruptions - therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Dexamethasone - adverse effects | Male | Boron Compounds - administration & dosage | Dose-Response Relationship, Drug | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Nausea - therapy | Aged, 80 and over | Adult | Leukocyte Count | Glycine - administration & dosage | Thalidomide - adverse effects | Drug Eruptions - etiology | Hematologic Diseases - chemically induced | Dexamethasone - administration & dosage | Double-Blind Method | Drug Administration Schedule | Administration, Oral | Peripheral Nervous System Diseases - therapy | Thalidomide - administration & dosage | Hematologic Diseases - therapy | Vomiting - chemically induced | Platelet Count | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Boron Compounds - adverse effects | Aged | Vomiting - therapy | Complications and side effects | Corticosteroids | Analysis | Multiple myeloma | Nausea | Backache | Lithium compounds | Thrombocytopenia | Edema | Back pain | Dexamethasone | Toxicity | Exanthema | Feasibility studies | Diarrhea | Peripheral neuropathy | Patients | Bleeding | Side effects | Pain | Vomiting | Constipation | Tourmaline | Index Medicus | Haematological Malignancy | Research Paper
Journal Article
European journal of haematology, ISSN 0902-4441, 03/2010, Volume 84, Issue 3, pp. 266 - 270
dexamethasone | refractory disease | cyclophosphamide | thalidomide | transplantation | Hodgkin's lymphoma | Cyclophosphamide | Transplantation | Dexamethasone | Refractory disease | Thalidomide | Life Sciences & Biomedicine | Hematology | Science & Technology | Procarbazine - administration & dosage | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prednisolone - administration & dosage | Humans | Salvage Therapy | Drug Resistance, Neoplasm | Male | Transplantation, Autologous | Vinblastine - administration & dosage | Hodgkin Disease - surgery | Cisplatin - administration & dosage | Hodgkin Disease - radiotherapy | Organoplatinum Compounds - administration & dosage | Hodgkin Disease - drug therapy | Vincristine - administration & dosage | Adult | Paclitaxel - administration & dosage | Doxorubicin - administration & dosage | Dacarbazine - administration & dosage | Prednisone - administration & dosage | Antibodies, Monoclonal, Murine-Derived | Dexamethasone - administration & dosage | Deoxycytidine - administration & dosage | Rituximab | Etoposide - administration & dosage | Combined Modality Therapy | Vidarabine - analogs & derivatives | Bleomycin - administration & dosage | Thalidomide - administration & dosage | Remission Induction | Cytarabine - administration & dosage | Melphalan - administration & dosage | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Topotecan - administration & dosage | Mechlorethamine - administration & dosage | Vidarabine - administration & dosage | Peripheral Blood Stem Cell Transplantation | Deoxycytidine - analogs & derivatives | Carmustine - administration & dosage | Antimitotic agents | Stem cells | Antineoplastic agents | Hodgkin's disease | Steroids | Index Medicus
Journal Article
Biology of blood and marrow transplantation, ISSN 1083-8791, 2009, Volume 15, Issue 6, pp. 718 - 723
Hematology, Oncology and Palliative Medicine | Myeloma | Stem cell mobilization | Autotransplant | Transplantation | Immunology | Life Sciences & Biomedicine | Hematology | Science & Technology | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Hematopoietic Stem Cell Mobilization - methods | Humans | Middle Aged | Heterocyclic Compounds - pharmacology | Male | Transplantation, Autologous | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Recombinant Proteins | Filgrastim | Thalidomide - analogs & derivatives | Angiogenesis Inhibitors - administration & dosage | Multiple Myeloma - drug therapy | Granulocyte Colony-Stimulating Factor - antagonists & inhibitors | Antineoplastic Agents - adverse effects | Treatment Failure | Angiogenesis Inhibitors - therapeutic use | Vincristine - administration & dosage | Adult | Female | Antineoplastic Agents - pharmacology | Retrospective Studies | Angiogenesis Inhibitors - adverse effects | Multiple Myeloma - surgery | Bone Marrow - drug effects | Doxorubicin - administration & dosage | Multiple Myeloma - blood | Thalidomide - adverse effects | Ifosfamide - pharmacology | Dexamethasone - administration & dosage | Heterocyclic Compounds - administration & dosage | Risk Factors | Etoposide - pharmacology | Etoposide - administration & dosage | Combined Modality Therapy | Thalidomide - administration & dosage | Granulocyte Colony-Stimulating Factor - pharmacology | Leukapheresis | Ifosfamide - administration & dosage | Cyclophosphamide - pharmacology | Aged | Multiple Myeloma - radiotherapy | Thalidomide - therapeutic use | Peripheral Blood Stem Cell Transplantation | Granulocyte Colony-Stimulating Factor - administration & dosage | Chemotherapy | Care and treatment | Granulocyte colony-stimulating factor | Analysis | Multiple myeloma | Stem cells | Angiogenesis inhibitors | Cancer | Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 10/2016, Volume 375, Issue 14, pp. 1319 - 1331
Journal Article